Open access
Open access
Powered by Google Translator Translator

Pharmacology

Cluster-randomized trial: Postexposure hydroxychloroquine does not prevent Covid-19 in healthy persons exposed to a PCR-positive case patient

25 Nov, 2020 | 09:15h | UTC

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 – New England Journal of Medicine

 

Commentary on Twitter

 


With more data on its COVID-19 vaccine, Russian institute offers new evidence of success

25 Nov, 2020 | 09:13h | UTC

With more data on its COVID-19 vaccine, Russian institute offers new evidence of success – Science

News release: SECOND interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose – Sputnik V

Commentaries: Expert reaction to press release reporting the second interim analysis of the efficacy of the Sputnik V vaccine – Science Media Centre AND Russia says Sputnik V virus vaccine 95% effective – MedicalXpress

 


Latest COVID-19 guidelines come out against bamlanivimab, remdesivir

25 Nov, 2020 | 09:10h | UTC

Latest COVID-19 guidelines come out against bamlanivimab, remdesivir – ACP Internist

 


Systematic review: Financial payments from the pharmaceutical industry is associated with more physician prescribing of the drug made by the company that they got the payments from

25 Nov, 2020 | 09:07h | UTC

Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? A Systematic Review – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentary: Financial payments from drug industry associated with physician prescribing – American College of Physicians

 

Commentary from the author on Twitter  (thread – click for more)

 


Why the AstraZeneca-Oxford Covid-19 vaccine is different. It does not require extremely cold temperatures for storage, and the price will be “a fraction” of the expense of the other vaccine candidates

24 Nov, 2020 | 09:32h | UTC

Why the AstraZeneca-Oxford Covid-19 vaccine is different – Vox

 


Why does the AstraZeneca-Oxford COVID-19 vaccine’s efficacy vary so much? Here’s what we know

24 Nov, 2020 | 09:30h | UTC

Why Does the AstraZeneca COVID-19 Vaccine’s Efficacy Vary So Much? Here’s What We Know – TIME

Related: Why Oxford’s positive COVID vaccine results are puzzling scientists – Nature

 


Emergency COVID-vaccine approvals pose a dilemma for scientists. It could complicate efforts to study long-term outcomes, such as safety, how long protection lasts and whether the jab prevents infection or just the disease

24 Nov, 2020 | 09:28h | UTC

Why emergency COVID-vaccine approvals pose a dilemma for scientists – Nature

 


Four reasons why we need multiple vaccines for Covid-19

24 Nov, 2020 | 09:27h | UTC

Four reasons why we need multiple vaccines for Covid-19 – Wellcome Trust

 


Randomized, placebo-controlled, crossover trial: Amantadine, modafinil, and methylphenidate are no better than placebo for fatigue in multiple sclerosis

24 Nov, 2020 | 09:02h | UTC

Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial – The Lancet Neurology (link to abstract – $ for full-text)

 


Covid-19: Oxford University vaccine shows 70% protection

23 Nov, 2020 | 09:54h | UTC

Covid-19: Oxford University vaccine shows 70% protection – BBC

News release: Oxford University breakthrough on global COVID-19 vaccine

 

Commentary on Twitter

 


Systematic review: Ultra-long‐acting insulins provide modest benefit compared to NPH insulin for Type 2 DM, resulting in reduced risk of hypoglycemia but no difference in HbA1c

23 Nov, 2020 | 09:45h | UTC

(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus – Cochrane Library

Summary: (Ultra-)long-acting insulin analogues compared with NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus

 


Updated WHO guideline on drugs for Covid-19 rejects Remdesivir and strongly recommends Corticosteroids for patients with severe and critical disease

20 Nov, 2020 | 08:51h | UTC

A living WHO guideline on drugs for covid-19 – The BMJ

Commentary: WHO Guideline Development Group advises against use of remdesivir for COVID-19 – British Medical Journal

 

Commentary on Twitter

 


Phase 2 trial of Oxford COVID-19 vaccine finds it is safe and provokes immune response in young as well as in older adults

20 Nov, 2020 | 08:50h | UTC

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Commentaries: Covid: Oxford vaccine shows ‘encouraging’ immune response in older adults – BBC AND Age and frailty in COVID-19 vaccine development – The Lancet AND Expert reaction to phase 2 trial safety and immunogenicity data from the Oxford COVID-19 vaccine trial including in healthy older adults – Science Media Centre AND Phase 2 trial of Oxford COVID-19 vaccine in healthy older adults finds it is safe and provokes immune response – The Lancet

 

Commentary on Twitter

 


Opinion: Improving care for heart failure with reduced ejection fraction—a potential polypill-based strategy

20 Nov, 2020 | 08:37h | UTC

Improving Care for Heart Failure With Reduced Ejection Fraction—A Potential Polypill-Based Strategy – JAMA

 


Pfizer and BioNTech to submit Covid-19 vaccine data to FDA as full results show 95% efficacy

19 Nov, 2020 | 09:36h | UTC

Pfizer and BioNTech to submit Covid-19 vaccine data to FDA as full results show 95% efficacy – STAT

News release: Pfizer and Biontech conclude phase 3 study of Covid-19 vaccine candidate, meeting all primary efficacy endpoints

Commentaries: ‘Incredible milestone for science.’ Pfizer and BioNTech update their promising COVID-19 vaccine result – Science AND Pfizer: COVID-19 shot 95% effective, seeking clearance soon – Associated Press AND Expert reaction to announcement by Pfizer that they have concluded the Phase III study of their COVID-19 vaccine candidate after demonstrating 95% efficacy – Science Media Centre AND Covid vaccine: Pfizer says ‘94% effective in over-65s’ – BBC

 


Opinion: For billion-dollar COVID vaccines, basic government-funded science laid the groundwork

19 Nov, 2020 | 09:33h | UTC

For Billion-Dollar COVID Vaccines, Basic Government-Funded Science Laid the Groundwork – Scientific American

 


Temperature concerns could slow the rollout of new coronavirus vaccines

19 Nov, 2020 | 09:31h | UTC

Temperature concerns could slow the rollout of new coronavirus vaccines – Science

 


#AHA20 [not published yet] Randomized trial: After drug-eluting stent implantation, one-month dual antiplatelet therapy (DAPT) followed by aspirin monotherapy was noninferior to 6-12 months of DAPT

19 Nov, 2020 | 09:21h | UTC

One-Month Dual Antiplatelet Therapy Followed by Aspirin Monotherapy After Drug-Eluting Stent Implantation – One-Month DAPT – American College of Cardiology

Commentary: Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT – TCTMD

 


Chinese Covid-19 vaccine candidate (CoronaVac) appears safe and induces an immune response in healthy volunteers in phase 1/2 clinical trial

18 Nov, 2020 | 09:19h | UTC

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet

Commentaries: Covid-19: Chinese vaccine ‘successful in mid-stage trials’ – BBC AND Expecting the unexpected with COVID-19 vaccines – The Lancet Infectious Diseases

 

Commentary on Twitter

 


#AHA20 – RCT: Sotagliflozin improved cardiovascular outcomes in patients with Diabetes and CKD. Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo

18 Nov, 2020 | 09:08h | UTC

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk – SCORED – American College of Cardiology

 


#AHA20 – RCT: Sotagliflozin improved cardiovascular outcomes in patients with Diabetes and Recent Worsening Heart Failure. Diarrhea and severe hypoglycemia were more common with sotagliflozin than with placebo

18 Nov, 2020 | 09:06h | UTC

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure – SOLOIST-WHF – American College of Cardiology

 


#AHA20 – Randomized trial: Among patients with recurrent pericarditis, Rilonacept was associated with lower risk of pericarditis recurrence than placebo

18 Nov, 2020 | 09:04h | UTC

Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Rilonacept Prevents Recurrent Pericarditis: RHAPSODY – TCTMD AND Rilonacept inHibition of interleukin-1 Alpha and beta for recurrent Pericarditis: a pivotal Symptomatology and Outcomes stuDY – RHAPSODY – American College of Cardiology AND Trial shows drug effective in 96% of patients with recurrent pericarditis – Cleveland Clinic

 

Commentary on Twitter

 


Opinion: A new important study supports wider use of the polypill

18 Nov, 2020 | 09:01h | UTC

Richard Smith: A new important study supports wider use of the polypill – The Lancet

Original study and commentaries: Randomized trial: A polypill comprising statins, multiple blood pressure lowering drugs, and aspirin prevents cardiovascular events among patients at intermediate cardiovascular risk

 

Commentary on Twitter

 


Systematic review: Management of primary headaches in pregnancy

18 Nov, 2020 | 09:00h | UTC

Management of Primary Headaches in Pregnancy – Agency for Healthcare Research and Quality

Full report: Management of Primary Headaches in Pregnancy

Evidence Summary: Management of Primary Headaches in Pregnancy

 


[Press release – not published yet] Moderna’s COVID-19 vaccine candidate shows 94.5% protection in an interim analysis of the phase 3 COVE study

17 Nov, 2020 | 09:55h | UTC

Press release: Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study

See also: Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures

Commentaries: What Moderna’s Covid-19 vaccine results mean for ending the pandemic – Vox AND Moderna follows Pfizer with exciting vaccine news – how to read these dramatic developments – The Conversation AND Moderna’s COVID Vaccine Is  95% Effective – Independent NIH-Appointed Board Assessment – Higher Storage Temperature Make It Even Better News – Health Policy Watch AND Moderna’s Vaccine News “Encouraging” But Won’t Solve Immediate Problem of Virus Surge in Europe & Americas – WHO – Health Policy Watch AND COVID vaccine excitement builds as Moderna reports third positive result – Nature AND Moderna’s Covid-19 vaccine is strongly effective, early look at data show – STAT AND With strong data on two Covid-19 vaccines, we have more answers about the road ahead — and questions too – STAT AND Early data show Moderna’s COVID vaccine 94.5% effective – CIDRAP AND A Note Of Caution On Moderna’s Promising Covid-19 Vaccine News – Forbes AND Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine – NIH News Releases AND Moderna: Covid vaccine shows nearly 95% protection – BBC AND Latest vaccine success is good news but high price may restrict access – The Guardian AND ‘Just beautiful’—Another COVID-19 vaccine, from newcomer Moderna, succeeds in large-scale trial – Science AND Moderna trial success gives world more hope in race to end pandemic – Reuters AND Expert reaction to Moderna announcement of its phase 3 vaccine interim results – Science Media Centre

 


Stay Updated in Your Specialty

 

No spam, just news.